Indication
MALT lymphoma
5 clinical trials
7 products
2 drugs
Clinical trial
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Subjects With Mature B-Cell MalignanciesStatus: Recruiting, Estimated PCD: 2025-03-01
Product
SGR-1505Clinical trial
ILyAD (Indolent Lymphoma And Vitamin D) A Phase III Double Blind, Randomized Trial to Evaluate the Supplemental Effect of Vitamin D on Progression-free Survival in Patients With Low Tumor-burden Indolent Non-Hodgkin Lymphoma Treated With RituximabStatus: Active (not recruiting), Estimated PCD: 2023-07-21
Drug
VarlilumabProduct
AzacitidineClinical trial
A Phase I/IB Pilot Study of CC-486 Combined With Lenalidomide and Obinutuzumab for Relapsed/Refractory Indolent B-Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-04-01
Product
LenalidomideProduct
ObinutuzumabClinical trial
A Phase II Study of Chlorambucil in Combination With Subcutaneous Rituximab Followed by Maintenance Therapy With Subcutaneous Rituximab in Patients With Extranodal Marginal Zone B-cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT Lymphoma)Status: Active (not recruiting), Estimated PCD: 2016-03-01
Product
ChlorambucilProduct
RituximabClinical trial
Phase 2 Trial of Lenalidomide (Revlimid)-Dexamethasone + Rituximab in Recurrent Small B-Cell Non-Hodgkin Lymphomas (NHL) Resistant to RituximabStatus: Completed, Estimated PCD: 2012-11-14
Drug
lenalidomideProduct
Dexamethasone